ARTICLE | Company News
Nabi, Kedrion S.p.A. deal
July 3, 2006 7:00 AM UTC
Kedrion received an exclusive license to commercialize NABI's Civacir in the EU. The polyclonal antibody is being developed to prevent recurrence of HCV-related liver disease in HCV-positive liver tr...